Atlas FDA

Novoste™ Beta-Cath™ System

FDA premarket approval P000018/S051 · decided 2024-09-26

Approval details

PMA number
P000018
Supplement
S051
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
Novoste™ Beta-Cath™ System
Generic name
Intravascular radiation delivery system
Applicant
Best Vascular, Inc.
Date received
2023-05-05
Decision date
2024-09-26
Days to decision
510 days
Decision code
APPR
Product code
MOU
Advisory committee
Cardiovascular
Expedited review
No
Location
Norcross, GA
Statement
approval for a reduction in the existing minimum dose rate of the Jacketed Radiation Source Trains (JRST) of the Beta-Cath 3.5Fr System from 64.4 mGy/s to 58.5 mGy/s.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.